Company news
Apollomics Inc. news in 2023
Apollomics Inc.'s news releases, calls and decks from 2023, newest first.
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
December 3, 2023
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
November 27, 2023
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
November 15, 2023
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
October 30, 2023
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
October 25, 2023
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
October 22, 2023
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
October 15, 2023
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
September 27, 2023
Decks in 2023
- ESMO 2023
Conference · 13 slides · 2023